Spectrum Pharmaceuticals

.

FDA OK’s Spectrum Cancer Drug for Wider Use

Spectrum Pharmaceuticals

An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.

Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.

Latest News

Staples to see Protests from Postal Workers
Even Though Boeing Profit’s Fall by 12.7%
It’s Time for a makeover for Ronald McDonald
Stockpiles Scale in U.S but Brent Steady
Qualcomm’s Growth in China Slowed as Customers Wait for New Technology
Mark Pincus Withdraws from Operations of Zynga Amid Restructuring Plans
Kiwi Rises as RBNZ Hikes Interest Rates
Housing Supply Less Than Home Buyer Demand
GE Plans to Bid for Alstom
Valeant Gains Following Takeover Bid But Slips Again
Abortion-rights advocates condemn mid-pregnancy abortion ban
Californian mother reaches settlement over breast milk dispute with TSA
Syndicate content